Your browser doesn't support javascript.
loading
Digoxin is Not Related to Mortality in Patients with Heart Failure: Results from the SELFIE-TR Registry.
Çetin Güvenç, Rengin; Güvenç, Tolga Sinan; Çaglar, Mert Efe; Al Arfaj, Abdullah Ayar; Behrad, Ailin; Yilmaz, Mehmet Birhan.
Afiliación
  • Çetin Güvenç R; Division of Cardiology, Department of Internal Medical Sciences, Istanbul Okan University School of Medicine, Tepeören Mahallesi Tuzla Kampüsü, 34959, Istanbul, Turkey. rcguvenc1@gmail.com.
  • Güvenç TS; Division of Cardiology, Department of Internal Medical Sciences, Istinye University School of Medicine, Istanbul, Turkey.
  • Çaglar ME; Division of Cardiology, Department of Internal Medical Sciences, Istanbul Okan University School of Medicine, Tepeören Mahallesi Tuzla Kampüsü, 34959, Istanbul, Turkey.
  • Al Arfaj AA; Division of Cardiology, Department of Internal Medical Sciences, Istanbul Okan University School of Medicine, Tepeören Mahallesi Tuzla Kampüsü, 34959, Istanbul, Turkey.
  • Behrad A; Division of Cardiology, Department of Internal Medical Sciences, Istanbul Okan University School of Medicine, Tepeören Mahallesi Tuzla Kampüsü, 34959, Istanbul, Turkey.
  • Yilmaz MB; Division of Cardiology, Department of Internal Medical Sciences, Dokuz Eylul University School of Medicine, Istanbul, Turkey.
Am J Cardiovasc Drugs ; 24(3): 399-408, 2024 May.
Article en En | MEDLINE | ID: mdl-38573460
ABSTRACT

AIMS:

Digoxin has been used in the treatment for heart failure for centuries, but the role of this drug in the modern era is controversial. A particular concern is the recent observational findings suggesting an increase in all-cause mortality with digoxin, although such observations suffer from biased results since these studies usually do not provide adequate compensation for the severity of disease. Using a nationwide registry database, we aimed to investigate whether digoxin is associated with 1-year all-cause mortality in patients with heart failure irrespective of phenotype.

METHODS:

A total of 1014 out of 1054 patients in the registry, of whom 110 patients were on digoxin, were included in the study. Multivariable adjustments were done and propensity scores were calculated for various prognostic indicators, including signs and symptoms of heart failure and functional capacity. Crude mortality, mortality adjusted for covariates, mortality in the propensity score-matched cohort, and Bayesian factors (BFs) were analyzed.

RESULTS:

Crude 1-year mortality rate did not differ between patients on and off digoxin (17.3% vs 20.1%, log-rank p = 0.46), and digoxin was not related to mortality following multivariable adjustment (hazard ratio 0.87, 95% confidence interval 0.539-1.402, p = 0.57). Similarly, all-cause mortality was similar in 220 propensity-score adjusted patients (17.3% vs 20.0%, log-rank p = 0.55). On Bayesian analyses, there was moderate to strong evidence suggesting a lack of difference between in unmatched cohort (BF10 0.091) and weak-to-moderate evidence in the matched cohort (BF10 0.296).

CONCLUSIONS:

In this nationwide cohort, we did not find any evidence for an increased 1-year mortality in heart failure patients on digoxin.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Sistema de Registros / Digoxina / Insuficiencia Cardíaca Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Am J Cardiovasc Drugs Asunto de la revista: ANGIOLOGIA / CARDIOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2024 Tipo del documento: Article País de afiliación: Turquía Pais de publicación: Nueva Zelanda
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Sistema de Registros / Digoxina / Insuficiencia Cardíaca Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Am J Cardiovasc Drugs Asunto de la revista: ANGIOLOGIA / CARDIOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2024 Tipo del documento: Article País de afiliación: Turquía Pais de publicación: Nueva Zelanda